The pharmaceutical world is seeing a major shift in blood sugar management with the arrival of GLP-1 skin applications. These devices offer a potentially more user-friendly alternative to subcutaneous administrations of GLP-1 receptor agonists, minimizing the requirement of daily needle pokes. The innovation delivers the medication directly through